Researchers at Kessler Foundation and the Cleveland Clinic have published one of the longest longitudinal studies of cognition in multiple sclerosis (MS). The article, "Cognitive impairment in multiple sclerosis: An 18-year ...
Jun 24, 2014
0
0
(Medical Xpress)—New treatments for inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, diabetes and autism could be on the horizon, after a global University of Melbourne – lead study successfully mapped ...
Jun 16, 2014
0
0
Multiple sclerosis manifests itself in many different ways and different courses. A recent effort to fine-tune descriptions – or phenotypes—of MS was undertaken by an international team of leaders in MS research and clinical ...
Jun 4, 2014
0
0
There appears to be no link between chronic cerebrospinal venous insufficiency and multiple sclerosis (MS), according to new research published in CMAJ (Canadian Medical Association Journal).
Jun 2, 2014
0
0
Until now, scientists have not known exactly how inflammation weakens the Blood-Brain Barrier, allowing toxins and other molecules access to the brain. A new research report appearing in the June 2014 issue of The FASEB Journal ...
Jun 2, 2014
0
0
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment for clinical trials, and treatment decision-making. Researchers at Icahn ...
May 28, 2014
0
0
(Medical Xpress)—Virginia Commonwealth UniversitySchool of Medicine researchers have uncovered a new mechanism of action of fingolimod, a drug widely used to treat multiple sclerosis: elimination of adverse or traumatic ...
May 28, 2014
0
0
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute of Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. ...
May 28, 2014
0
0
(Medical Xpress)—A team of researchers working at Virginia Commonwealth University in the U.S. has found that giving fingolimod, a drug normally used to treat Multiple Sclerosis (MS) in people, to mice, caused them to lose ...
EPFL start-up Anokion has the immune system in its sights. The company has developed technology for retraining white blood cells that holds promise for treating autoimmune, allergic, and a number of other diseases. A group ...
May 5, 2014
0
0
